NICE Rejects Celgene’s Clinically-Effective Revlimid On Cost Grounds
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE has decided not to recommend Celegene’s Revlimid for myelodysplastic syndromes despite finding it clinically effective, due to its high cost.